Physician profile
Blake Henchcliffe
NPI 1982191409
$6,382.01
in general payments reported to CMS, 2019-2025
19 companies · $690 in 2025
The $690 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,083 · 2023: $2,875 · 2024: $733 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,187 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,187.14 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,198.74 | 2022-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,093.67 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $726.58 | 2022-2025 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $640.83 | 2022-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $606.88 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $539.63 | 2022-2025 | Auvelity |
| Alkermes, INC. | $452.04 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Lundbeck LLC | $364.64 | 2022-2025 | Rexulti |
| Abbvie INC. | $236.73 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $116.56 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $91.93 | 2022-2024 | Jornay Pm |
| Janssen Scientific Affairs, LLC | $84.51 | 2024 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $75.92 | 2023 | Trintellix |
| Corium, LLC | $45.20 | 2022 | |
| Acadia Pharmaceuticals INC | $36.37 | 2022-2023 | Nuplazid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $22.12 | 2023 | |
| Neuronetics, INC. | $19.58 | 2023 | Neurostar Tms Therapy System |
| Vanda Pharmaceuticals INC. | $17.28 | 2024 | Fanapt |
| Avanir Pharmaceuticals, INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Henchcliffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.